Trials / Unknown
UnknownNCT04315480
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis
Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Università Politecnica delle Marche · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia correlated to SARS-CoV2 infection. Aim of the study is to test the hypothesis that an anti-IL6 treatment can be effective in calming the virus-induced cytokine storm, blocking deterioration of lung function or even promoting a rapid improvement of clinical conditions, preventing naso-tracheal intubation and/or death.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tocilizumab | single intravenous administration 8mg/Kg |
Timeline
- Start date
- 2020-03-12
- Primary completion
- 2020-04-09
- Completion
- 2020-05-01
- First posted
- 2020-03-19
- Last updated
- 2020-04-13
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04315480. Inclusion in this directory is not an endorsement.